Can a diabetes drug shield transplanted kidneys?

NCT ID NCT06560801

Recruiting now Disease control Sponsor: University of Erlangen-Nürnberg Medical School Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether dapagliflozin, a drug used for diabetes and kidney protection, can improve kidney structure and blood flow in people who received a kidney transplant one year ago. About 48 participants will be randomly assigned to take dapagliflozin or standard care alone. Researchers will examine kidney biopsies and MRI scans to look for changes in inflammation, scarring, and perfusion.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dapagliflozin (a diabetes drug that helps protect the kidneys)
What this could lead to: If it works, this could show that dapagliflozin helps preserve kidney health in transplant patients, potentially leading to better long-term outcomes.
What could go wrong: This is a small, early-phase study (48 people) looking at tissue changes, not hard outcomes like kidney failure. The drug may not show clear benefits or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC KIDNEY DISEASES

Contacts and locations

Locations

Clinical Research Center (CRC)
RECRUITING

Erlangen, Bavaria, 91054, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.